Followers | 46 |
Posts | 4493 |
Boards Moderated | 0 |
Alias Born | 07/26/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, May 05, 2020 6:35:40 PM
In response to the urgent demand posed by the COVID-19 global pandemic, Altimmune has created a COVID-19 vaccine candidate and is currently preparing for immunogenicity studies and manufacture of Phase 1 clinical trial material. Initially, Altimmune will work with UAB investigators on preclinical animal studies and characterization of the vaccine immunogenicity with the goal of enabling a Phase 1 trial in Q3 of this year. Altimmune has significant experience in the development of intranasal vaccines for respiratory pathogens, including NasoVAX, a seasonal and pandemic influenza vaccine candidate, and NasoShield, a vaccine candidate for inhalation anthrax. NasoShield is being developed under a $133.7 million contract with Biomedical Advanced Research and Development Authority (BARDA).
“It is critical that the biotechnology industry and academic institutions work together to prevent the further spread of COVID-19, and UAB is an ideal partner to support us in this effort,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer. “UAB has an impressive track record of cutting-edge research in virology and immunology, as well as in the clinical development of vaccines. In fact, Altimmune was founded through a technology license from UAB in 1997. We are excited to collaborate with UAB in our efforts and look forward to addressing this crisis together.”
“We are eager to collaborate with Altimmune on this important project," said Frances E. Lund, the Charles H. McCauley Professor and Chair for the UAB Department of Microbiology. “The expertise and infrastructure at UAB will be invaluable to the rapid progression of this vaccine into clinical studies,” she added.
Six UAB labs will work together on this urgent collaboration with Altimmune. “This project will be our highest priority for the group in the next few months as the goal is to get the data to Altimmune as rapidly as possible, so that they will use the information gained from the preclinical study to design their clinical trial in people,” Lund said.
UAB also has extensive experience in conducting clinical studies of vaccines and has participated in studies sponsored by the Vaccine Evaluation and Trial Unit, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
AdCOVID is a single-dose, intranasal vaccine candidate designed to protect against COVID-19, the disease caused by the SARS-CoV-2 virus. By utilizing the Company’s proprietary intranasal vaccine technology, it is expected that AdCOVID has the potential to activate multiple arms of the immune system as shown in a recent Phase 2 clinical study with NasoVAX, an influenza vaccine candidate based on the same platform technology. That study showed potent stimulation of mucosal and cellular immune responses in addition to a strong serum antibody response. In addition, our platform vaccines (NasoVAX and NasoShield) have shown an excellent stability profile and, when combined with the simple intranasal route of administration, may allow for efficient and inexpensive distribution of the vaccine.
About UAB
Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham is an internationally renowned research university and academic medical center, as well as Alabama’s largest employer, with some 23,000 employees, and has an annual economic impact exceeding $7 billion on the state. The pillars of UAB’s mission include education, research, innovation and economic development, community engagement, and patient care. Learn more at www.uab.edu.
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and vaccines. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™, NasoShield™ and AdCOVID™). For more information on Altimmune, please visit www.altimmune.com.
https://finance.yahoo.com/news/altimmune-university-alabama-birmingham-collaborate-110010768.html
Recent ALT News
- Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 07/03/2024 09:45:00 AM
- Altimmune to Participate at Leerink Partners Therapeutics Forum • GlobeNewswire Inc. • 07/02/2024 11:30:00 AM
- Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 06/28/2024 09:45:00 AM
- Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt • GlobeNewswire Inc. • 06/26/2024 11:30:00 AM
- Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT • PR Newswire (US) • 06/25/2024 09:45:00 AM
- Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions • GlobeNewswire Inc. • 06/23/2024 05:45:00 PM
- Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions • GlobeNewswire Inc. • 06/22/2024 08:45:00 PM
- Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT • PR Newswire (US) • 06/20/2024 09:45:00 AM
- Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions • GlobeNewswire Inc. • 06/18/2024 11:30:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT • PR Newswire (US) • 06/17/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT • PR Newswire (US) • 06/10/2024 09:45:00 AM
- Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - ALT • PR Newswire (US) • 06/05/2024 09:45:00 AM
- Altimmune to Participate at Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/29/2024 11:31:00 AM
- Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024 • GlobeNewswire Inc. • 05/29/2024 11:30:00 AM
- The Gross Law Firm Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming Deadline • PR Newswire (US) • 05/29/2024 09:45:00 AM
- Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM) • PR Newswire (US) • 05/21/2024 01:00:00 PM
- The Gross Law Firm Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT • PR Newswire (US) • 05/21/2024 09:45:00 AM
- Contact The Gross Law Firm by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT) • PR Newswire (US) • 05/14/2024 09:45:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Moore Law PLLC Encourages Investors in Altimmune Inc. to Contact Law Firm • PR Newswire (US) • 05/09/2024 09:51:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:05:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:04:51 AM
- Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 05/09/2024 11:00:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM